These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8495272)

  • 21. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
    Laine L; Bombardier C; Hawkey CJ; Davis B; Shapiro D; Brett C; Reicin A
    Gastroenterology; 2002 Oct; 123(4):1006-12. PubMed ID: 12360461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated.
    Metcalfe S; Dougherty S; McNee W
    BMJ; 2003 Feb; 326(7384):334; author reply 334. PubMed ID: 12575714
    [No Abstract]   [Full Text] [Related]  

  • 23. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis.
    Jones ST; Clague RB; Eldridge J; Jones DM
    Br J Rheumatol; 1991 Feb; 30(1):16-20. PubMed ID: 1991209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NSAID toxicity: where are we and how do we go forward?
    Hawkey CJ
    J Rheumatol; 2002 Apr; 29(4):650-2. PubMed ID: 11950001
    [No Abstract]   [Full Text] [Related]  

  • 25. Gastrointestinal events related to the use of non-steroidal anti-inflammatory drugs: some clinical and economic aspects.
    Eliakim R; Rachmilewitz D
    Isr J Med Sci; 1997 Oct; 33(10):696-9. PubMed ID: 9397147
    [No Abstract]   [Full Text] [Related]  

  • 26. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
    Morgan RW
    N Engl J Med; 1999 Oct; 341(18):1397; author reply 1398-9. PubMed ID: 10577091
    [No Abstract]   [Full Text] [Related]  

  • 27. [Nonsteroidal anti-inflammatory agents--choice between disturbances of gastrointestinal tract and cardiovascular toxicity].
    Gumbrevicius G; Milasius A; Sveikata A
    Medicina (Kaunas); 2006; 42(5):429-39. PubMed ID: 16778472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A perspective on the cost-effectiveness and risks of non-steroidal anti-inflammatory drug therapy.
    Champion GD
    Med J Aust; 1988 Oct; 149(7):346-9. PubMed ID: 3050396
    [No Abstract]   [Full Text] [Related]  

  • 29. Controversies in COX-2 selective inhibition.
    Simon LS; Smolen JS; Abramson SB; Appel G; Bombardier C; Brater DC; Breedveld FC; Brune K; Burmester GR; Crofford LJ; Dougados M; DuBois RN; Fitzgerald GA; Frishman W; García Rodríguez LA; Hochberg MC; Kalden JR; Laine L; Langman MJ; Prescott SM; van de Putte LB; Whelton A; White WB; Willaims GH
    J Rheumatol; 2002 Jul; 29(7):1501-10. PubMed ID: 12136912
    [No Abstract]   [Full Text] [Related]  

  • 30. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
    Alekseeva LI
    Ter Arkh; 2010; 82(8):57-62. PubMed ID: 20873248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is rofecoxib safer than naproxen?
    Adelman A
    J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
    [No Abstract]   [Full Text] [Related]  

  • 32. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword.
    Lichtenstein DR; Syngal S; Wolfe MM
    Arthritis Rheum; 1995 Jan; 38(1):5-18. PubMed ID: 7818572
    [No Abstract]   [Full Text] [Related]  

  • 33. Life after Vioxx: the clinical implications.
    Fortun PJ; Hawkey CJ
    Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854
    [No Abstract]   [Full Text] [Related]  

  • 34. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
    Singh G; Ramey DR; Morfeld D; Shi H; Hatoum HT; Fries JF
    Arch Intern Med; 1996 Jul; 156(14):1530-6. PubMed ID: 8687261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis.
    Jajić Z; Malaise M; Nekam K; Koó E; Dankó K; Kovacs M; Scarpignato C
    Clin Exp Rheumatol; 2005; 23(6):809-18. PubMed ID: 16396699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of non-steroidal antirheumatic drug-induced gastrointestinal lesions with misoprostol].
    Bach GL; Stock KP; Hüdepohl M
    Z Rheumatol; 1991; 50(3):175-80. PubMed ID: 1927064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenbufen and indomethacin in the treatment of rheumatoid arthritis. A comparative double-blind, crossover study.
    Ammitzbøll F
    Scand J Rheumatol Suppl; 1979; (23):5-10. PubMed ID: 373083
    [No Abstract]   [Full Text] [Related]  

  • 38. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    Deeks JJ; Smith LA; Bradley MD
    BMJ; 2002 Sep; 325(7365):619. PubMed ID: 12242171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of upper gastrointestinal lesions in patients taking chronic nonsteroidal anti-inflammatory drug therapy.
    Zuckerman MJ; Hernández JA; Marwah RK; Pema KM; Gupta TP; al-Samman M
    Am J Gastroenterol; 1997 Feb; 92(2):363-4. PubMed ID: 9040233
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.